Pancreatic Cancer Research

ResearcherWayne State UniversityNo recent work listed

Sanjeev Banerjee

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5112013421. Sources: OpenAlex.

Their work

Papers
24 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2011: 8 papers · 2012: 5 papers · 2013: 4 papers · 2014: 3 papers · 2015: 3 papers · 2016: none · 2017: none · 2018: 1 paper

Papers 24

  1. Retraction notice to "Notch-1 induces Epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells". Co-author DOI 10.1016/j.canlet.2018.03.020↗
  2. Parenterally administrable nano-micelles of 3,4-difluorobenzylidene curcumin for treating pancreatic cancer. First author DOI 10.1016/j.colsurfb.2015.05.007↗
  3. Hyaluronic acid-conjugated polyamidoamine dendrimers for targeted delivery of 3,4-difluorobenzylidene curcumin to CD44 overexpressing pancreatic cancer cells. Co-author DOI 10.1016/j.colsurfb.2015.09.043↗
  4. Hyaluronic Acid Engineered Nanomicelles Loaded with 3,4-Difluorobenzylidene Curcumin for Targeted Killing of CD44+ Stem-Like Pancreatic Cancer Cells. First author DOI 10.1021/acs.biomac.5b00941↗
  5. Deregulation of miR-146a expression in a mouse model of pancreatic cancer affecting EGFR signaling. Co-author DOI 10.1016/j.canlet.2014.05.013↗
  6. Pancreatic cancer stem-like cells display aggressive behavior mediated via activation of FoxQ1. Co-author DOI 10.1074/jbc.m113.532887↗
  7. Differentially expressed miRNAs in cancer-stem-like cells: markers for tumor cell aggressiveness of pancreatic cancer. Co-author DOI 10.1089/scd.2013.0551↗
  8. Activated K-Ras and INK4a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype. Co-author DOI 10.1002/jcp.24162↗
  9. Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures. Co-author DOI 10.1002/mnfr.201200297↗
  10. Synthesis, characterization and anti-tumor activity of novel thymoquinone analogs against pancreatic cancer. First author DOI 10.1016/j.bmcl.2013.03.003↗
  11. CXCR2 macromolecular complex in pancreatic cancer: a potential therapeutic target in tumor growth. Co-author DOI 10.1593/tlo.13133↗
  12. Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer. First author DOI 10.1002/jcp.24036↗
  13. Inclusion complex of novel curcumin analogue CDF and β-cyclodextrin (1:2) and its enhanced in vivo anticancer activity against pancreatic cancer. Co-author DOI 10.1007/s11095-012-0700-1↗
  14. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Co-author DOI 10.1158/1940-6207.capr-11-0299↗
  15. Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. Co-author DOI 10.1371/journal.pone.0050165↗
  16. Genistein inhibits cell growth and induces apoptosis through up-regulation of miR-34a in pancreatic cancer cells. Co-author DOI 10.2174/138945012804545597↗
  17. Restoring sensitivity to oxaliplatin by a novel approach in gemcitabine-resistant pancreatic cancer cells in vitro and in vivo. Co-author DOI 10.1002/ijc.25658↗
  18. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. Co-author DOI 10.1002/jcb.23150↗
  19. The complexities of obesity and diabetes with the development and progression of pancreatic cancer. Co-author DOI 10.1016/j.bbcan.2010.11.003↗
  20. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Co-author DOI 10.1016/j.canlet.2011.03.012↗
  21. Pancreatic cancer: understanding and overcoming chemoresistance. Co-author DOI 10.1038/nrgastro.2010.188↗
  22. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0017850↗
  23. Activated K-ras and INK4a/Arf deficiency cooperate during the development of pancreatic cancer by activation of Notch and NF-κB signaling pathways. First author DOI 10.1371/journal.pone.0020537↗
  24. Network modeling of CDF treated pancreatic cancer cells reveals a novel c-myc-p73 dependent apoptotic mechanism. Co-author PMID 21904657↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Fazlul H. Sarkar · 24 shared papers, 2011–2018 · strength 0.90
  2. Shadan S. Ali · 15 shared papers, 2011–2018 · strength 0.53
  3. Bin Bao · 15 shared papers, 2011–2018 · strength 0.51
  4. Asfar Sohail Azmi · 12 shared papers, 2011–2018 · strength 0.41
  5. Subhash Padhyé · 8 shared papers, 2011–2015 · strength 0.33
  6. Yiwei Li · 9 shared papers, 2011–2018 · strength 0.32
  7. Zhiwei Peter Wang · 6 shared papers, 2011–2018 · strength 0.22
  8. Amro Aboukameel · 6 shared papers, 2011–2014 · strength 0.21
  9. Prashant Kesharwani · 3 shared papers, 2015 · strength 0.19
  10. Arun K. Iyer · 3 shared papers, 2015 · strength 0.19
  11. Lucio Miele · 5 shared papers, 2011–2018 · strength 0.18
  12. Philip A. Philip · 4 shared papers, 2011–2014 · strength 0.13
  13. Murray Korc · 3 shared papers, 2011–2013 · strength 0.09
  14. Ramzi M. Mohammad · 2 shared papers, 2011–2014 · strength 0.07
  15. Zhiwei Wang · 2 shared papers, 2011–2012 · strength 0.05
  16. Mansi A. Parasramka · 1 shared paper, 2013 · strength 0.04
  17. SmitiV. Gupta · 1 shared paper, 2013 · strength 0.04
  18. Yusufi Mujahid · 1 shared paper, 2013 · strength 0.04
  19. Xiaoqing Guan · 1 shared paper, 2013 · strength 0.03
  20. Shuo Wang · 1 shared paper, 2013 · strength 0.03
  21. Bhanu P. Jena · 1 shared paper, 2013 · strength 0.03
  22. Chunying Li · 1 shared paper, 2013 · strength 0.03
  23. Prasad R. Dandawate · 1 shared paper, 2012 · strength 0.03
  24. Jun Xia · 1 shared paper, 2012 · strength 0.03
  25. Jia Ma · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.